

## Boston Scientific Announces €80M Investment and 400+ Jobs at Clonmel Site

Taoiseach Leo Varadkar joins company's 25-year anniversary celebrations in Clonmel



*Exterior view of Boston Scientific Clonmel campus*

**CLONMEL, IRELAND (19 May 2023)** - Boston Scientific Corporation (NYSE: BSX) will today announce an €80 million investment in its Clonmel operations at an event celebrating the site's 25<sup>th</sup> anniversary with Taoiseach Leo Varadkar. The funding, supported by the Irish government through IDA Ireland, will go towards the continued expansion of the company's medical technology manufacturing and research and development (R&D) capabilities and is expected to enable 400+ jobs in the coming years.

The new investment will increase office and manufacturing space and transition the entire site to source more than 90% of its energy needs from renewable sources. This is part of the company's broader sustainability commitment to achieve carbon neutrality by 2030.\*

"Boston Scientific has been steadily growing its footprint in Ireland for the past quarter century," said Taoiseach Leo Varadkar. "Ireland is a global leader in the life sciences sector, and the decision by the company to invest again in Clonmel shows real confidence in the talent and infrastructure available."

The company's Clonmel site includes a Centre of Excellence for metal additives used in a range of electronic components for medical technology. Hiring is underway for positions in highly specialised roles within production, engineering, quality, supply chain and R&D functions.

"Our growth in the region has been possible thanks to our talented workforce here in Clonmel," said Conor Russell, vice president, Operations, Boston Scientific. "Our team has worked to build strong manufacturing and R&D capabilities and also a high-performing and inclusive culture that we are proud to continue to foster as an employer of choice."

Boston Scientific employees based in Clonmel manufacture medical devices that support the treatment of more than 400,000 patients globally each year. Products created in Clonmel help patients suffering from conditions such as heart disease, neurological disorders, kidney stones, and diseases of the pancreas, bile ducts and esophagus.

"Boston Scientific in Ireland has transformed its activities over its 30 years here" said Mary Buckley, executive director with IDA Ireland. "We welcome this investment in R&D and further manufacturing, which will offer new opportunities and careers in Tipperary and the region from the largest life sciences employer in Ireland."

IDA Ireland is tasked with attracting investment into Ireland by foreign-owned companies with a focus on jobs growth and industrial transformation in high growth sectors including MedTech. The agency supports a wide range of multinational companies with operations in Ireland through grants and other business supports in compliance with EU and Irish legislation.

Boston Scientific also recently renovated part of the Clonmel facility to create a more agile and collaborative space for its growing workforce and to further support an innovative environment. As a result, the site received a commercial interior design award as Project of the Year Workplace Interiors 5,000-15,000 square foot category at the UK Mixology Awards, which recognise the best projects, products and people in commercial interior design.

Learn more about Boston Scientific job opportunities at <https://www.bostonscientific.com/en-EU/careers>

###

\*Inclusive of all manufacturing and key distribution sites only (scopes 1 and 2).

## **ABOUT BOSTON SCIENTIFIC**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit [www.bostonscientific.eu](http://www.bostonscientific.eu) and connect on [Twitter](#) and [Facebook](#).

## **CONTACTS**

Siubhan Lafferty,

Media Relations EMEA

Boston Scientific

087 9150137 [EMEA.MediaRelations@bsci.com](mailto:EMEA.MediaRelations@bsci.com)

Lauren Tengler,

Investor Relations

Boston Scientific

001 (508) 683-5670 (office) [BSXInvestorRelations@bsci.com](mailto:BSXInvestorRelations@bsci.com)

---

<https://news.bostonscientific.eu/Clonmel-Investment>